Latest Headlines

  1. Labcorp Announces FDA Approval Of Companion Diagnostic Supporting Patients With Advanced Melanoma 8/10/2026

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.

  2. QIAGEN Receives U.S. FDA Clearance For First QIAstat-Dx Bloodstream Infection Panel 8/10/2026

    QIAGEN today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.

  3. ECI's Product & Packaging Testing Laboratory Achieves ISO/IEC 17025 Accreditation 8/10/2026

    ECI announced today that its Product & Packaging Testing Laboratory, located in the Coyol Free Zone in Costa Rica, has achieved ISO/IEC 17025:2017 accreditation from A2LA for technical competence in mechanical testing.

  4. Synnovis Milestone: 2,000 Revolutionary Blood Tests For NHS Lung And Breast Cancer Patients 8/10/2026

    SYNLAB is pleased to announce that Synnovis* have supported this initiative from its pilot phase and now provide ctDNA testing for over a third of eligible NHS patients in England.

  5. Blood Test Could Speed Lymphoma Diagnosis In Resource-Limited Settings 8/7/2026

    For people with lymphoma, getting the right diagnosis can be a race against time.

  6. GSI Group Expands Platform With Acquisition Of Aven Tools 8/6/2026

    GSI Group Holdings ("GSI Group") announces it has acquired Aven Tools, a leading designer and manufacturer of proprietary precision tools, instruments, and accessories.

  7. CellCarta Adds Tempus To CDx Commercialization Lab Network 8/6/2026

    CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, today announced a strategic collaboration with Tempus AI, Inc. Under the agreement, CellCarta will include Tempus in its CDx Commercialization Lab Network as the network’s second commercial laboratory partner, strengthening oncology-focused companion diagnostics offerings to biopharma sponsors.

  8. ECU Health Microbiology Lab Launches bioMérieux VITEK REVEAL Analyzer 8/5/2026

    ECU Health Medical Center is the fifth institution in the nation to begin using the bioMérieux VITEK REVEAL analyzer, a rapid blood culture testing tool that can help providers identify effective antibiotics for certain bloodstream infections approximately 24 hours sooner than standard methods.

  9. Eastern Caribbean Countries Strengthen Molecular Diagnostic Capacity To Enhance Preparedness For Emerging Infectious Diseases 8/5/2026

    Laboratory professionals from across the Eastern Caribbean have enhanced their capacity to rapidly detect and respond to infectious diseases with epidemic and pandemic potential following a regional workshop on molecular diagnostics hosted by the Pan American Health Organization/World Health Organization (PAHO/WHO), in collaboration with the Caribbean Public Health Agency (CARPHA) and the Best-dos Santos Public Health Laboratory, a PAHO/WHO Collaborating Centre on Antimicrobial Resistance Surveillance.

  10. Leeds NHS Innovation To Accelerate Global Adoption Of AI-Enabled Pathology For Cancer Diagnostics Through Epredia Partnership 8/5/2026

    A pioneering pathology technology developed by Leeds Teaching Hospitals NHS Trust is set for international deployment after securing a commercial agreement with Epredia, a global leader in precision cancer diagnostics solutions. NHS is the UK's National Health Service.